 |
Top 10 Eye Disease and Blindness treatment startups in USA
Oct 12, 2024 | By Jason Kwon | 22 |
2
Funding: $54M
XP Health is an artificial intelligence-powered vision benefits platform for employees.
XP Health is an artificial intelligence-powered vision benefits platform for employees.
3
Funding: $763.8M
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
4
Funding: $694.9M
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
5
Funding: $317.8M
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
6
Funding: $318M
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
7
Funding: $218.5M
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.
8
Funding: $173.4M
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
9
Funding: $153.9M
Through dedication and innovation, Second Sight's mission is to develop, manufacture and market implantable visual prosthetics to enable blind individuals to achieve greater independence. The Argus II Retinal Prosthesis System (“Argus II”) is also known as the bionic eye or the retinal implant. It is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa.
Through dedication and innovation, Second Sight's mission is to develop, manufacture and market implantable visual prosthetics to enable blind individuals to achieve greater independence. The Argus II Retinal Prosthesis System (“Argus II”) is also known as the bionic eye or the retinal implant. It is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa.
10
Funding: $139.5M
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
